Clinical TrialJun 23, 2026, 08:31 AM
Alpha Tau Treats First Glioblastoma Patient Outside US with Alpha DaRT
AI Summary
Alpha Tau Medical announced the successful treatment of the first glioblastoma patient in Israel, and the first ever outside of the United States, using its Alpha DaRT® therapy. The procedure, performed at Hadassah University Medical Center, utilized the company's proprietary brain applicator and marks the first international clinical application of Alpha DaRT’s brain-specific delivery system. This milestone is significant for Alpha Tau's glioblastoma program, especially for patients with recurrent glioblastoma who have limited treatment options.
Key Highlights
- Alpha Tau treated the first glioblastoma patient outside the US with Alpha DaRT.
- The procedure was performed at Hadassah University Medical Center in Jerusalem, Israel.
- It marks the first international clinical application of Alpha DaRT’s brain-specific delivery system.
- Glioblastoma is the most common and aggressive primary brain cancer, with ~160,000 new cases annually.
- The patient, a 77-year-old male with recurrent glioblastoma, was treated under the ALL clinical protocol.
- The procedure was completed safely and without unexpected complications.
Price Impact
More from DRTS